Kynetyka Technologies Pty Ltd
ABN 88 614 880 956
65 Hardys Road Underdale SA 5032
www.kynetyka.com.au

MEDIA RELEASE

Kynetyka Secures AusHealth Funding to Support DVTect® Development.

28 July 2025; Adelaide Australia: Kynetyka Technologies Pty Ltd ("Kynetyka"), a privately held Adelaide-based medical device company, is delighted to announce that it has secured funding of $500,000 from AusHealth, an Australian medical research charity.

Kynetyka CEO Craig Newton said "This welcome investment will support the development of DVTect®, a point-of-care test for deep vein thrombosis, by funding a clinical study at the Royal Adelaide Hospital and software development at Adelaide-based HeartAI. Working in close partnership, the data collected from the study will be used to optimize DVTect® and provide robust sensitivity and specificity statistics as required by clinicians and regulators. These are crucial milestones leading ultimately to integrating DVTect®into routine clinical practice."

According to AusHealth CEO Justin Coombs, "DVTect® has the potential to accelerate DVT diagnosis, save lives and reduce healthcare costs both here in Australia and around the world. Kynetyka's project is a great example of the Australian MedTech innovation that AusHealth is proud to support on the path to patient impact."

Xenia Sango, Chair of Kynetyka, said "We are grateful for AusHealth's investment. We also deeply value the quality of the development partners available in Adelaide. The combined expertise and experience of the Royal Adelaide Hospital, Flinders University's Medical Device Research Institute and HeartAI will be vital for the successful realization of DVTect®."

For further information, contact Kynetyka Technologies Pty Ltd:

Craig Newton, CEO and MD
cnewton@kynetyka.com.au
Phone: +61 (0)434 674 256

Gavin Preston, Investor Relations
gavin@behindthecounter.com.au
Phone: +61 (0)481 947 839

Kynetyka Technologies Pty Ltd

Kynetyka Technologies Pty Ltd (Kynetyka) is an Australian medical device company headquartered in Adelaide. The company is developing and commercialising DVTect®, a unique, patented, point-of-care software and device designed to detect deep vein thrombosis quickly and accurately.

Kynetyka is led by a team of experienced professionals, supported by leading clinical and technology advisors. The executive team has collectively over 120 years of global experience in the medical, pharmaceutical, and technology development sectors. They have the right skills and knowledge to expedite development and commercialise DVTect®, improving detection and diagnosis of DVT, enhancing patient outcomes, and ultimately saving lives.

AusHealth

AusHealth is a self-funded medical research charity with headquarters in Adelaide. It was established in 1985 (then called Medvet) as the research commercialisation arm of the Royal Adelaide Hospital and remains affiliated with the Central Adelaide Local Health Network ('CALHN').
Since its inception, AusHealth has contributed more than $50 million to Australian led research in disease therapies, AI-powered clinical solutions and novel healthcare technologies. As well as funding researchers, it dedicates itself to 'translating' great ideas into investment-ready entities, aiming to retain the commercial benefits of Australian ideas and grow the nation's health tech sector.

AusHealth has two commercial arms: AusHealth Hospitals (which provides revenue management services to the healthcare sector); and AusHealth Diagnostics (Australia's largest provider of workplace drug and alcohol testing). The organisation employs more than 300 people, delivering services across all states and territories.

All proceeds from these commercial enterprises go towards more than a dozen medical research endeavours. These projects are collectively managed by AusHealth Ventures, which operates out of a new research hub called The Accelerator, where entrepreneurs, innovators and health tech specialists collaborate. The bricks and mortar hub is located in Underdale, Adelaide; it opened in 2024.

Deep Vein Thrombosis (DVT)

DVT is a serious condition where a blood clot forms in a vein, typically in the leg. If undiagnosed or untreated, it can lead to life-threatening complications such as pulmonary embolism.

Currently, suspected DVT is most commonly confirmed via ultrasound, which is expensive and requires significant capital equipment and expertise. Further, only 20-25% of patients referred for ultrasound are found to have a DVT.

The US Centers for Disease Control and Prevention (CDC) estimates that up to 900,000 DVT cases and 100,000 DVT-related deaths occur annually in the USA, while in Australia, DVT contributes to approximately 8,000 deaths every year.

We estimate that up to 40% of DVT cases are missed during clinical assessment. While ultrasound is the standard diagnostic tool, 75- 80% of ultrasounds for suspected DVT return negative results. Due to delays in accessing ultrasound and blood tests, many patients are treated with anticoagulant medications out of caution. This approach carries risks, including bleeding and other complications, particularly when treatment is given unnecessarily.

DVTect® Technology

DVTect® is a novel, patented, medical device that combines software and sensor technology to detect DVT. It is portable, affordable, and simple to use. It is designed for use by healthcare professionals and also non- medically trained personnel.

When a patient has a deep vein thrombosis (DVT) in the leg, there is a measurable change in the calf muscle's response to movement. The DVTect® test starts with a sensor attached to the leg, which is lightly tapped to cause movement in the muscle. The sensor captures the resulting 3D waveform data and transmits it to the DVTect® software, which analyses the signal to detect the presence of DVT. Results are displayed instantly on a smart device or computer.

DVTect® is faster and easier to use than ultrasound devices. It has the potential to reduce unnecessary ultrasounds, avoid preventable deaths from pulmonary embolism, and the overuse of anticoagulants. Use of DVTect® could result in an estimated healthcare cost saving of over $4 billion per year in the USA and Australia.

Currently in development, DVTect® is initially targeted for use in hospitals, including post-surgery recovery wards, intensive care units, and emergency departments. Future expansion will introduce DVTect® into community settings including general practice/primary care, aged care, maternal health and regional and remote communities.